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The transcriptional activity of human immunodeficiency virus type 1 (HIV-1) is affected by many cellular
factors. Homologies near the HIV-1 initiator region to the DNA-binding sequences of YY1, a multifunctional
transcription factor known to regulate diverse viral and cellular promoters, suggested that YY1 might regulate
HIV-1. Antibody to YY1 blocked the formation of complexes by HeLa cell nuclear extract and a DNA
oligonucleotide encoding the HIV-1 initiator region. HIV-1 long terminal repeat (LTR) expression, as
measured the expression of a transfected LTR-CAT reporter gene, was repressed more than 12-fold by the
cotransfection of a YY1 expression vector. HIV-1 production by both COS-1 and CEM cells after transfection
of an infectious molecular HIV-1 clone was repressed 7- to 20-fold by cotransfection of a YY1 expression vector.
HIV-1 production was also decreased threefold in a CD4-positive lymphocyte cell line chronically infected with
HIV-1 (8E5) after transfection of YY1. In situ hybridization studies confirmed that YY1 reduced HIV-1 RNA
expression. YY1 may play an important role in the regulation of HIV-1 LTR expression in vivo and virus
production by infected cells.
Intensive study has shown that the long terminal repeat
(LTR), the promoter of human immunodeficiency virus type 1
(HIV-1), responds to numerous cellular factors (10-14, 22, 31).
While many of these factors augment LTR expression, no
cellular factor has been shown to directly decrease production
of HIV-1 virions by infected cells. Nevertheless, HIV-1 mRNA
is expressed in only a small percentage of infected cells (6, 7,
25). The HIV-1 activating protein Tat powerfully stimulates
transcription of all viral messages (14). Factors that regulate
LTR expression in the basal state, before the accumulation of
a threshold quantity of Tat, must play a central role in the
restriction of HIV-1 mRNA expression.
Factors known to bind to and regulate the HIV-1 LTR are
found in abundance in lymphocytes, a primary cellular target
of HIV-1. YY1, a multifunctional human transcription factor,
regulates both viral and lymphocyte promoters (3, 8, 26-28).
USF recognizes the HIV-1 initiator region and shares with
YY1 an affinity for the TdT initiator (5, 27). Homologies
between DNA sequences known to bind YY1 and the HIV-1
initiator region suggested that YY1 might regulate the HIV-1
promoter.
We report evidence that YY1 recognizes the initiator region
of the HIV-1 LTR. YY1 decreased LTR-directed gene expres-
sion. Cotransfection of a YY1 expression vector with an
infectious molecular HIV-1 clone resulted in diminished virus
production in several cell lines. Similarly, expression of YY1 in
chronically HIV-1-infected T-cell lines reduced the expression
of HIV-1 RNA and viral particles. As YY1 did not significantly
repress Tat-activated LTR expression but repressed HIV-1
production in vivo, we suggest that YY1 exerts its effect at a
critical stage in the HIV-1 life cycle.
* Corresponding author. Mailing address: Program in Molecular
Medicine, University of Massachusetts Medical Center, 373 Plantation
St., Suite 309, Worcester, MA 01605. Phone: (508) 856-1987. Fax:
(508) 856-5473.
MATERILLS AND METHODS
Plasmids and cell lines. The T-cell lines CEM, 8E5, and
ACH2 were maintained in suspension culture in RPMI 1640
medium (ICN Biochemicals, Costa Mesa, Calif.) supple-
mented with 10% fetal bovine serum (GIBCO, Grand Island,
N.Y.). COS-1 and HeLa cells were grown in monolayers in
Dulbecco's modified Eagle's medium (GIBCO) supplemented
with 10% fetal bovine serum. The HIV-1 LTR-chloramphen-
icol acetyltransferase (CAT) reporter gene construct pILIC
(1), the infectious molecular clone of HIV-1 pNL4-3 (1), the
Tat expression vector pcTat (30), and the P-galactosidase
expression plasmid pSV-3gal (19) were prepared by the stan-
dard alkaline lysis method. pCMV-YY1 was constructed by
insertion of a StyI-EcoRI fragment of the YY1 cDNA plasmid
(28) into the BamHI site of the expression vector pCMV-bam/
neo3 (15).
Transfections, CAT assays, and p24 ELISA. Monolayer cells
were transfected with 20 ,Lg of plasmid DNA by the calcium
phosphate procedure (21) with 5 p,g of LTR-CAT reporter, 5
or 10 p,g of effector DNA, and carrier DNA. Suspension
cultures were transfected by the DEAE-dextran method (21)
with 1.5 ,ug of LTR-CAT reporter or 2 ,g of pNL4-3 and 1 to
4 pug of effector DNA. CAT assays were performed 48 h after
normalization for total protein content (21). To measure
transfection efficiency, pSV-Pgal was cotransfected and ,B-gal-
actosidase assays were performed as described previously (19).
Aliquots of culture medium were sampled for detection of
HIV-1 p245ag protein. Assays were performed with an antigen
capture Coulter enzyme-linked immunosorbent assay (ELISA)
kit according to the manufacturer's instructions.
Antibody depletion in EMSAs. Electrophoretic mobility shift
assays (EMSAs) with HeLa nuclear extract were performed as
described previously with an oligonucleotide corresponding to
the -16 to +27 sequence of the HIV-1 LTR (5'-TGCTllTr
GCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA
G-3' [21]). The EMSA with YY1 protein was performed as
described by Shi et al. (28). For depletion experiments, YY1
antiserum or preimmune serum (gift of T. Shenk) was added to
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FIG. 2. Inhibition of LTR-directed CAT expression by YY1 in
transfected CEM cells. Fold inhibition was calculated by dividing the
percentage of acetylated chloramphenicol when the HIV-1 LTR-CAT
reporter was transfected alone by the percentage of acetylated chlor-
amphenicol when the reporter was cotransfected with pCMV or
pCMV-YY1. Values of less than 1 indicate activation; cotransfection
of pCMV resulted in weak activation or inhibition, and cotransfection
of pCMV-YYI resulted in significant inhibition. Values represent the
mean and standard deviation for four experiments.
FIG. 1. Electrophoretic mobility shift complexes formed by HeLa
cell nuclear extract and an oligonucleotide encoding the HIV-1 LTR
from - 17 to +25 with respect to the transcriptional start. Formation
of complexes previously shown to be specifically inhibited by unlabeled
oligonucleotide (20) was inhibited by YY1 antiserum but not by
preimmune serum. A nonspecific complex (20) was unaffected by YY1
antiserum or preimmune serum.
the EMSA reaction mixture and incubated for a further hour
at 4°C; 5 RI of 10% Staphylococclus aureus Cowan cells
(Pansorbin; Calbiochem, La Jolla, Calif.) was then added and
incubated for an hour at 4°C. The reaction mixture was
centrifuged, and the supernatant was run on an acrylamide gel
as described before (21).
Detection of HIV-1 RNA by in situ hybridization. Cells were
fixed in 4% paraformaldehyde, and in situ hybridization with
alkaline phosphatase detection was performed as described
before (29).
RESULTS
YYI antibody interferes with a DNA-protein interaction
near the HIV-1 initiator region. Several lines of evidence
suggest that YYI can recognize the HIV-1 LTR initiator
region. Bacterially synthesized YY1 protein (gift of Y. Shi)
bound an oligonucleotide encoding the LTR - 16 to +27
region in EMSAs (data not shown). YYI is present in HeLa
cell nuclear extracts (28). In EMSA competition experiments
with HeLa nuclear extract, the labeled LTR - 16/+27 probe,
and competitor representing the KE3' YY1 binding site (8) of
the immunoglobulin kappa light chain 3' enhancer (5'-CCAC
CTCCATCTTG-3'), more than a 30-fold molar excess of KE3'
competitor was required to prevent complex formation. In the
converse experiment, complexes bound to the labeled KE3'
probe were preferentially inhibited by a 10-fold molar excess of
the LTR oligonucleotide (data not shown).
The effect of YY1 antiserum on EMSA complexes formed
with the LTR oligonucleotide provided further evidence that
YY1 is involved in complex formation. In previous EMSA
studies, we have found one nonspecific and several specific
complexes formed by this oligonucleotide and HeLa nuclear
extract (21). YY1 antiserum interfered with the formation of
specific complexes by a HeLa nuclear protein and the LTR
initiator region, while preimmune serum did not interfere with
complex formation (Fig. 1). Nonspecific complexes were unaf-
fected by YY1 antiserum.
YYI is capable of direct interaction with both DNA and
other cellular factors (19). Together, our findings suggest that
YYI or an immunologically related protein complex recog-
nizes the HIV-1 initiator region.
YY1 represses LTR-directed CAT activity. The ability of
YY1 to decrease LTR-directed expression of CAT was tested.
CEM cells, a CD4-positive lymphocyte line, were cotransfected
with the HIV-1 LTR-CAT reporter and pCMV-YY1. In
control experiments, the reporter was cotransfected with the
unmodified expression vector pCMV-bam/neo3. Compared
with the activity of the reporter transfected with the unmodi-
fied vector, pCMV-YY1 caused up to 12-fold repression in a
dose-dependent manner (Fig. 2). Expression of pSV-3gal, as
measured by assays of ,B-galactosidase activity, varied by less
than 10% between selected cultures. Repression was not
dependent on promoter sequences upstream of the NF-KB
sites, as a reporter (pLTR dl-525/-98 [24]) lacking those
sequences was repressed to the same extent as the construct
carrying the complete LTR (data not shown). YY1 had a
marginal effect on activation mediated by cotransfection with
pcTat (data not shown).
YY1 decreases HIV-1 production in nonlymphoid cells. To
assess the biological relevance of the repression mediated by
Hela cell nuclear extract
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FIG. 3. Inhibition of p24"'1` production in COS-1 cells. HIV-1 DNA was transfected with pCMV or pCMV-YYl. (A) Concentrations of p24
measured after transfection. For simplicity, data are shown only for 10 pLg of pCMV (designated HIV-1); the values for 5 ,ug of pCMV were nearly
identical. Results are representative of three experiments. (B) Fold inhibition was calculated by dividing p24 values measured after cotransfection
of HIV-1 DNA and pCMV by values measured after cotransfection of HIV-1 and the indicated amount of pCMV-YY1.
FIG. 4. One day after transfection of COS-1 cells, HIV-1 mRNA was detected by in situ hybridization with alkaline phosphatase (27).
Nick-translated, biotinylated whole HIV-1 genomes were used as probes. Cells transfected with HIV-1 and pCMV-YY1 under phase (A) and
bright light (B); little dark hybridization signal is seen. Control cells transfected with HIV-1 and unmodified CMV expression vector under phase
(C) and bright light (D); copious dark hybridization signal is seen.
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FIG. 5. Inhibition of p24-ag production in CEM cells. Experiments and data calculations were performed as for Fig. 3. (A) Concentration of
p24. Results are representative of three experiments. (B) Fold inhibition.
YY1, the effect of YY1 on the expression of virus in a model
of acute infection was studied. COS-1 cells were cotransfected
with pCMV-YY1 or the unmodified vector and with pNLA-3,
an infectious and replication-competent molecular clone of
HIV-1. COS-1 cells can be efficiently transfected with and
support HIV-1 replication and production of infectious virus
by this clone (1).
Transfection of pCMV-YY1 resulted in a dose-dependent
decrease in the HIV p247ar level of nearly 20-fold by 1 day
posttransfection. Greater than threefold repression was main-
tained for up to 10 days in culture (Fig. 3). Cells grew to
confluency by day 3; there was no observable difference in
growth between cultures. YY1 did not affect the expression of
a cotransfected 3-galactosidase gene; expression varied by less
than 10% between selected cultures tested. In situ hybridiza-
tion studies of these cells showed decreased expression of
HIV-1 mRNA in cultures cotransfected with YY1 (Fig. 4).
YY1 decreases HIV-1 production in lymphoid cells. Similar
experiments were performed with CD4-positive CEM T cells.
Virus production was detected after 3 days in cultured cells
cotransfected with pNL4-3 and the unmodified expression
vector. In contrast, virus production in cultures cotransfected
with pCMV-YY1 was diminished up to sevenfold by 3 to 6 days
after transfection (Fig. 5) and then rose to levels comparable to
those in other cultures. Throughout the experiments, cell
viability, as measured by trypan blue dye exclusion and total
cell number, was not decreased by YY1 transfection.
YY1 decreases virus production in a T-cell line chronically
infected with HIV-1. To test the effect of YY1 on HIV-1
expression in cells which constitutively express the virus, 8E5
cells were transfected with YY1. 8E5 cells are CEM-derived
cells that contain a single integrated HIV-1 genome and
chronically express a low level of virus (9). Cells were trans-
fected with pCMV-YY1 or empty vector (Fig. 6A and B). YY1
repressed HIV-1 production up to threefold 2 days after
transfection (Fig. 6C). In situ studies (not shown) again
showed decreased HIV-1 mRNA expression in cells cotrans-
fected with YY1.
ACH2 cells are similar to 8E5 cells but produce high titers of
HIV-1 upon stimulation by tumor necrosis factor alpha or
tetradecanoyl phorbol acetate (TPA) (4). Expression of virus
in the basal state, before TPA stimulation, was repressed by
transfection of pCMV-YY1. However, YY1 did not block the
induction of virus after TPA stimulation (data not shown).
DISCUSSION
Integrated HIV-1 DNA is now known to be present in a
significant number of CD4-positive lymphocytes during all
stages of HIV-1 infection. Viral mRNA, however, is expressed
in only a fraction of these cells (6, 7, 25). Many cellular factors
have been shown to increase HIV-1 mRNA expression (10-14,
22, 31). Initial reports that the HIV-1 nef gene can downregu-
late viral expression were refuted by later studies (17, 20). As
mRNA expression is restricted despite the abundance of
stimulatory factors present in lymphocytes, cellular proteins
that downregulate HIV-1 LTR expression must play an impor-
tant role in the life cycle of HIV-1.
In vitro studies have shown that the cellular factor USF can
repress transcription via a binding site in the U3 region (11)
and can activate transcription through a site at the initiator (5).
LBP-1, first reported to activate transcription (13), has been
shown to decrease HIV-1 transcription in in vitro reactions
(16). The in vivo role of these factors is unclear.
We have shown that YY1, a cellular transcription factor
thought to be widely distributed (28), can downregulate HIV-1
expression. Evidence suggests that YY1 recognizes a site near
the initiator region and represses HIV-1 transcription. It
should be emphasized that we present no direct evidence that
a functional initiator element exists in the HIV-1 LTR (23) or
that YY1 directs initiator-mediated transcription of the LTR,
as it can in other promoters (27). It is interesting that when
acting through bona fide initiator elements, YY1 activates
transcription (2, 27). Our findings support the hypothesis that
the effect exerted by YY1 is critically dependent on interac-
tions with cellular factors.
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FIG. 6. Inhibition of p24*ag production in 8E5 cells. Only pCMV or
pCMV-YY1 was transfected, as 8E5 cells chronically produce HIV-1.
(A and B) Concentration of p24. Results are representative of three
experiments. (C) Fold inhibition was calculated by dividing p24 values
measured after transfection with pCMV by values measured after
transfection of the indicated amount of pCMV-YY1.
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Repression was not accounted for by cell death induced by
transfection of YY1, as viability measured by trypan blue dye
exclusion was unaffected by YY1. ,B-Galactosidase expression
was unaffected by YY1, suggesting that YY1 does not cause
nonspecific repression of transcription. In situ hybridization
studies demonstrate that repression is mediated at the level of
transcription.
For the first time, in tissue culture models of both acute and
chronic infection, we have shown that a cellular transcription
factor can decrease HIV-1 production. We observed repres-
sion in both nonlymphoid (COS-1) and lymphoid (CEM) cells.
Host cell differences may explain the different kinetics of
repression observed in these experiments. COS-1 cells are
CD4 negative, and so superinfection of cells by progeny virions
could not occur. It has been suggested that, after a transient
period of virus production, transfected HIV-1 DNA fails to
stably integrate into the chromosome of nonlymphoid cells (1).
These factors account for the plateau of virus production and
sustained effect of YY1 (see Fig. 3) in COS-1 cells. CEM
CD4-positive lymphocytes are susceptible to continued rounds
of viral replication and reinfection. Consistent with the tran-
sient nature of YY1 expression, the peak effect of YY1 was
seen 2 to 3 days after transfection of CEM cells. Similarly,
maximal repression of virus production in 8E5 cells, a line that
chronically produces HIV-1, coincided with the expected peak
of YY1 expression.
Repression by YY1 was not irreversible. Repression in
ACH2 cells could be ablated by mitogen activation. In the
context of transfection of a tat expression vector, YY1 is not
capable of significant repression of Tat-activated transcription
of an LTR-CAT reporter. However, YY1 can repress HIV-1
expression in models of acute and chronic infection in which
the amount of Tat present may be more biologically relevant.
YY1 can form protein-protein contacts with SP1 and per-
haps other basic transcription factors (18). Repression by YY1
is likely to be mediated by such interactions. It will be
important to determine whether YY1 interacts directly with
the LTR or in cooperation with other factors and whether YY1
competes with other factors that can recognize the HIV-1
initiator region.
Our observations suggest that YY1 restricts HIV-1 tran-
scription and production in the unstimulated state but allows
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viral expression after appropriate stimulation. The majority of
infected cells probably exist in such a state of "transcriptional
latency," capable of virus production upon appropriate activa-
tion. It will be important to determine the relative levels of
YYI present in a variety of cell types under a variety of
physiological conditions. Understanding of the mechanism of
YY1 action and how repression by YY1 is overcome by
activating signals may yield important insights into this critical
step in the life cycle of HIV-1.
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